| Similar Articles |
|---|
 |
Registered Rep.
August 30, 2011
Amy Burroughs |
When Your Client Has Alzheimer's One early sign of the disease is trouble managing money, which puts financial advisors on the front lines.   |
The Motley Fool
October 10, 2011
Frank Vinluan |
TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment. |
Entrepreneur
May 2006
Amanda C. Kooser |
Seniority Rules It's a smart time for entrepreneurs to get a jump start in the area of senior technology by creating products and services for this growing market. |
Financial Planning
August 1, 2009
Donna Mitchell |
Alzheimer's Toll A study surveyed 369 advisors in the U.S. to gauge their understanding of Alzheimer's and their preparedness for dealing with clients who have the disease. |
Registered Rep.
October 1, 2005
Gresham & Gresham |
The Golden Years? Besides being a great destroyer of health, dementia can also destroy many a grand retirement plan. Financial advisors need to prepare their clients for this possibility. |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
BusinessWeek
September 25, 2006
Catherine Arnst |
Chicken Soup For The Aging Brain The disputed idea that mental exercise can turn back time has launched an industry. |
Nurse Practitioner
August 2011
Davis et al. |
Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
The Motley Fool
August 27, 2007
Rich Duprey |
Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo. |
Chemistry World
October 14, 2009
Phil Taylor |
Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease. |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
Registered Rep.
February 13, 2015
Mark Miller |
Planning for Alzheimer's Carolyn McClanahan probably pays more attention to her clients' health than the typical financial planner. |
Chemistry World
August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
Entrepreneur
August 2004
Kim T. Gordon |
Young at Heart Are you making the mistake of lumping older baby boomers with seniors in your marketing campaign? There's a big distinction when marketing to these two groups. |
The Motley Fool
January 17, 2012
Brian Orelli |
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. |
